All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Emily Curran, University of Cincinnati, Cincinnati, US. We asked, How should we best sequence the new targeted therapies in relapsed B-ALL?
How should we best sequence the new targeted therapies in relapsed B-ALL?
To begin with, Curran discusses the approval of several novel agents such as CAR T-cell therapy, Inotuzumab , and blinatumomab, which have changed the treatment landscape in this field. She expands on what to consider when choosing the appropriate therapy for patients in the relapse setting, including efficacy, disease burden, toxicity, and whether the patient is a stem cell transplant candidate. Curran believes these are exciting times, with the field moving quickly forward which will lead to a better utilisation of novel agents in the future.
ESMO clinical practice guidelines: Targeted therapies for adult acute lymphoblastic leukemia
Here, we summarize the ESMO clinical practice guidelines published by Hoelzer et al., highlighting the latest developments and key recommendations for the...
A review of antibody and cellular immunotherapies for adults with relapsed/refractory ALL
The median age of diagnosis of acute lymphoblastic leukemia (ALL) in the United States is 16 years old, making it mainly a disease of children and adolescents;...
Subscribe to get the best content related to ALL delivered to your inbox